Sandoz, the generics and biosimilars arm of Novartis, has announced plans to invest EUR 150 million ($183 million) over next three to five years to expand antibiotic production capacity at its sites in Kundl, Austria and in Palafolls, Spain.  

In line with plans announced with the Austrian government in July 2020, Sandoz will invest more than EUR 100 million ($122 million) in the first phase of the expansion to introduce new manufacturing technology for the production of oral amoxicillin, an active pharmaceutical ingredient (API) for its penicillin product. The Kundl site is the company’s hub for API and finished dosage antibiotics production.

In addition to the investment in its Kundl site, Sandoz plans to invest approximately EUR 50 million ($61 million) at its site Palafolls, Spain for new production technology and increased capacity for the production of sterile penicillin APIs and sterile API mixtures.

As part of this network modernization plan, Sandoz will phase out current production of oral APIs at its site in Les Franqueses, Spain, which the company plans to close in 2024. Sterile API production is planned to transfer from the Kundl site to the new facility at Palafolls in 2025.

Source: Sandoz